Prostate cancer radiotherapy
Research activity in prostate cancer centers on radiation-based treatment strategies for localized and metastatic disease, with attention to intermediate-risk prostate cancer and oligometastatic hormone-sensitive prostate carcinoma.
- stereotactic body radiotherapy
- ultra-hypofractionated radiotherapy
- biochemical response
Clinical interest also includes combining radiotherapy with androgen deprivation therapy and relugolix to support disease control in prostate malignancy.
Hormone-sensitive metastatic disease
The sponsor is involved in studies for low-burden metastatic hormone-sensitive prostate cancer, with a focus on treatment approaches that integrate systemic hormonal therapy and targeted radiation to sites of metastatic involvement.
- apalutamide
- metastatic disease
- systemic therapy
These studies reflect a therapeutic interest in advanced androgen-driven malignancies and response assessment after combined modality treatment.
Breast cancer and endocrine therapy
Research also includes HR-positive, HER2-negative breast cancer in the neoadjuvant setting, with attention to patients who have node-positive and non-metastatic disease.
- preoperative radiotherapy
- elacestrant
- hormone receptor-positive disease
The therapeutic scope includes breast oncology alongside endocrine-based treatment strategies and radiation integration.
